Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Post Q2 2024 Earnings of ($0.36) Per Share

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDNFree Report) – Research analysts at Lifesci Capital issued their Q2 2024 EPS estimates for shares of Eledon Pharmaceuticals in a report issued on Tuesday, June 4th. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings per share of ($0.36) for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($1.16) per share. Lifesci Capital also issued estimates for Eledon Pharmaceuticals’ Q3 2024 earnings at ($0.37) EPS, Q4 2024 earnings at ($0.38) EPS and FY2024 earnings at ($1.47) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDNGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03.

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Eledon Pharmaceuticals in a research note on Tuesday.

View Our Latest Report on Eledon Pharmaceuticals

Eledon Pharmaceuticals Price Performance

Eledon Pharmaceuticals stock opened at $2.87 on Wednesday. Eledon Pharmaceuticals has a fifty-two week low of $1.07 and a fifty-two week high of $3.35. The stock’s fifty day moving average is $2.26 and its two-hundred day moving average is $1.86.

Institutional Investors Weigh In On Eledon Pharmaceuticals

A number of large investors have recently bought and sold shares of ELDN. CM Management LLC lifted its position in shares of Eledon Pharmaceuticals by 14.3% in the first quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $330,000 after acquiring an additional 20,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Eledon Pharmaceuticals by 39.4% in the 1st quarter. Vanguard Group Inc. now owns 969,121 shares of the company’s stock valued at $1,996,000 after purchasing an additional 273,703 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in Eledon Pharmaceuticals by 20.0% in the 4th quarter. Armistice Capital LLC now owns 2,189,000 shares of the company’s stock valued at $3,940,000 after purchasing an additional 365,000 shares in the last quarter. Institutional investors and hedge funds own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

(Get Free Report)

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

Read More

Earnings History and Estimates for Eledon Pharmaceuticals (NASDAQ:ELDN)

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.